Back to Markets
Earnings● Neutral
Biogen Anticipates Q1 Earnings Impact from R&D Charges
April 6, 2026 at 12:54 PMBy AlphaScalaSource: seekingalpha.com
Biogen expects a $0.19 per share hit to its first-quarter earnings driven by $34 million in research and development costs.
Biogen has issued a preliminary warning regarding its first-quarter financial results, citing an expected negative impact on net income. The biotechnology company projects a reduction of approximately $0.19 per share due to in-process research and development (IPR&D) charges totaling roughly $34 million. These adjustments are being disclosed ahead of the company’s formal first-quarter earnings report, which is scheduled for release on April 30.